Handelsbanken Fonder AB Buys Shares of 13,800 Tarsus Pharmaceuticals, Inc. $TARS

Handelsbanken Fonder AB bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 13,800 shares of the company’s stock, valued at approximately $1,130,000.

Several other institutional investors also recently bought and sold shares of the company. TimesSquare Capital Management LLC grew its position in Tarsus Pharmaceuticals by 24.3% in the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after acquiring an additional 64,941 shares in the last quarter. ProShare Advisors LLC grew its position in Tarsus Pharmaceuticals by 10.1% in the 4th quarter. ProShare Advisors LLC now owns 9,034 shares of the company’s stock valued at $740,000 after acquiring an additional 829 shares in the last quarter. Baader Bank Aktiengesellschaft grew its position in Tarsus Pharmaceuticals by 140.0% in the 4th quarter. Baader Bank Aktiengesellschaft now owns 12,000 shares of the company’s stock valued at $983,000 after acquiring an additional 7,000 shares in the last quarter. Valeo Financial Advisors LLC grew its position in Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after acquiring an additional 392 shares in the last quarter. Finally, F m Investments LLC acquired a new position in Tarsus Pharmaceuticals in the 4th quarter valued at about $3,213,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TARS has been the subject of several research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Guggenheim boosted their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $90.67.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 11,964 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $801,588.00. Following the completion of the sale, the chief executive officer owned 33,421 shares in the company, valued at $2,239,207. The trade was a 26.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William J. Phd Link sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $68.79, for a total value of $859,875.00. Following the sale, the director owned 116,332 shares of the company’s stock, valued at approximately $8,002,478.28. The trade was a 9.70% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 79,391 shares of company stock valued at $5,432,035. Corporate insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock opened at $61.16 on Wednesday. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The company has a market cap of $2.63 billion, a PE ratio of -53.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. The business has a 50-day simple moving average of $65.82 and a 200-day simple moving average of $71.27.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.